Israel China Biotechnology (ICB) Ltd (ICB) — Cash Flow-to-Debt Ratio
Israel China Biotechnology (ICB) Ltd (ICB) has a Cash Flow-to-Debt Ratio of -0.26x as of June 2021, meaning its operating cash flow of ILA-1.06 Million could theoretically repay 0% of its total liabilities (ILA4.11 Million) in one year. See ICB working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Israel China Biotechnology (ICB) Ltd Cash Flow-to-Debt Ratio (2015–2020)
Historical debt coverage capacity for Israel China Biotechnology (ICB) Ltd across 6 annual periods. Also explore Israel China Biotechnology (ICB) Ltd (ICB) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Israel China Biotechnology (ICB) Ltd (2015–2020)
Year-by-year debt coverage analysis for Israel China Biotechnology (ICB) Ltd. For market capitalisation and broader financial context, see market value of Israel China Biotechnology (ICB) Ltd.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2020 | -0.55x | ILA-4.34 Million | ILA7.87 Million | ▼ -26.3% |
| 2019 | -0.44x | ILA-4.22 Million | ILA9.68 Million | ▲ +77.4% |
| 2018 | -1.93x | ILA-4.75 Million | ILA2.46 Million | ▼ -74.6% |
| 2017 | -1.11x | ILA-3.17 Million | ILA2.87 Million | ▲ +39.7% |
| 2016 | -1.83x | ILA-3.94 Million | ILA2.15 Million | ▼ -15.1% |
| 2015 | -1.59x | ILA-3.81 Million | ILA2.39 Million | — |